FDA approves first epoetin alfa biosimilar for the treatment of anemia

May 15, 2018 – The U.S. Food and Drug Administration today approved epoetin alfa-epbx as a biosimilar to epoetin alfa for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. “It is important for patients to have access to safe, effective and … (leggi tutto)